Prostate Cancer Clinical Trial
Assessment of Research Digest Impact for Minority With Prostate Cancer, MiCAP Phase III Study
Summary
This phase III trial determines how well the Minority Prostate Cancer (MiCaP) Research Digest works in providing information to black men about the latest prostate cancer research. MiCaP Research Digest may be an effective method to help people learn about prostate cancer.This goal of this trial is to create educational programming that helps Black men make informed decisions about their prostate healthcare since Black men are diagnosed with prostate cancer more than any other race or ethnicity.
Full Description
PRIMARY OBJECTIVE:
I. To develop a research dissemination program, the Minority Prostate Cancer (MiCaP) Research Digest, which will spread information about CaP scientific discoveries, evidence-based interventions, and open clinical trials instantly among black males (BM).
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I: Participants watch MiCaP Research Digest video on study. Participants complete a survey throughout the trial.
ARM II: Participants watch an alternative video on study. Participants complete a survey throughout the trial.
Eligibility Criteria
Inclusion Criteria:
Identify as a Black male
Between the ages of 35 and 70
For virtual data collection, have access to the internet and Zoom (if joining study online)
For virtual data collection, reside anywhere in the U.S.
For in-person data collection, reside in one of the nine (9) catchment areas of the Mayo Clinic Cancer Center: Baker, Duval, Nassau, Clay, St. John's, Putnam, Flagler, Volusia and Brevard
Exclusion Criteria:
Identify as a race or ethnicity that is not Black
Identify as female
Be younger than age 35 and older than age 70
Lack access to internet and Zoom (if joining study online)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Jacksonville Florida, 32224, United States More Info
Principal Investigator
How clear is this clinincal trial information?